All contributors
Onconephrology contributor
Fervenza, Fernando C
Primarily MGRS & paraprotein kidney disease#16 of 47 recognizedHonor roll
50
Clinical papers
3,472
Citations (iCite)
2 / 10
First / senior author
2004–2026
Active years
Output over time
Clinical corpus papers per year — peak 7 in 2015.
- 2004: 1 paper
- 2005: 1 paper
- 2007: 1 paper
- 2008: 1 paper
- 2009: 1 paper
- 2010: 3 papers
- 2011: 4 papers
- 2012: 3 papers
- 2013: 2 papers
- 2014: 2 papers
- 2015: 7 papers
- 2016: 5 papers
- 2017: 2 papers
- 2018: 6 papers
- 2019: 1 paper
- 2020: 3 papers
- 2021: 2 papers
- 2022: 2 papers
- 2025: 2 papers
- 2026: 1 paper
20042026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
MGRS & paraprotein kidney disease44
Myeloma cast nephropathy25
Anticancer drug nephrotoxicity1
Checkpoint-inhibitor kidney injury1
Frequent collaborators
Other recognized contributors who most often share corpus papers with Fervenza (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Fervenza among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.